2026 Volume 73 Issue 3.4 Pages 410-415
Purpose:To investigate the associations between quantitative susceptibility mapping (QSM), amyloid positron emission tomography (PET) status, and clinical assessment scores in patients with mild cognitive impairment (MCI). Materials and Methods:This retrospective cross-sectional study analyzed 75 patients with clinically diagnosed MCI who underwent brain MRI with quantitative parameter mapping and amyloid PET. Based on visual assessment of amyloid PET images, participants were classified into an amyloid-positive (A+) group and an amyloid-negative (A−) group. Regional analyses of QSM values, brain volumetry, and cortical thickness were performed. Exploratory correlation analyses between QSM values and clinical assessment scores—including the Mini-Mental State Examination (MMSE), Revised Hasegawa Dementia Scale (HDS-R), Clinical Dementia Rating (CDR), and Self-Rating Depression Scale (SDS)—were primarily evaluated in the (A+) subgroup. Results:Region-specific differences in QSM values were observed between the (A+) and (A−) groups. In the amyloid-positive subgroup, QSM values in specific cortical regions correlated significantly with SDS and CDR scores, whereas no significant associations were identified with MMSE or HDS-R scores. Conclusion:QSM demonstrated region-specific alterations associated with affective and functional measures beyond amyloid status. These findings suggest that QSM may provide complementary information to conventional cognitive screening tests and may help characterize clinical heterogeneity in MCI. J. Med. Invest. 73 : 410-415, August, 2026